Numeric Investors’s Ultragenyx Pharmaceutical RARE Stock Holding History

Numeric Investors’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-3,700	Closed	-$415K	–	1107
2015 Q4	$415K	Buy	+3,700	New	+$370K	﹤0.01%	773
2015 Q1	–	Sell	-56,382	Closed	-$2.47M	–	1009
2014 Q4	$2.47M	Buy	+56,382	New	+$2.58M	0.03%	324

Other funds holding RARE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Numeric Investors's RARE Position: Q1 2016 in Review

Numeric Investors sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2016, closing a stake of 3,700 shares — an estimated $415K sold.

Numeric Investors first reported a position in RARE in Q4 2014 and held it in 2 quarters. The position peaked at $2.47M in Q4 2014. 161 funds tracked by Wall St. Rank hold RARE as of Q1 2016.

Numeric Investors reported no remaining Ultragenyx Pharmaceutical position as of Q1 2016 after selling out during the quarter.
Numeric Investors sold 3,700 Ultragenyx Pharmaceutical shares in Q1 2016, an estimated $415K.
Numeric Investors first reported a position in Ultragenyx Pharmaceutical in Q4 2014 and held it in 2 quarters.
Numeric Investors's Ultragenyx Pharmaceutical position peaked at $2.47M in Q4 2014.
161 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2016.

Based on Numeric Investors's 13F filing for Q1 2016, filed 6 May 2016.